BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China


Source: worldpharmatoday.com worldpharmatoday.com

Key Topics in this News Article:

News Snapshot:

BioNTech SE and Shanghai Fosun Pharmaceutical announced that the China National Medical Products Administration has approved the clinical trial in Mainland China for their mRNA vaccine candidate, BNT162b2. Wu Yifang, Chairman and CEO of Fosun Pharma , said: “As the ultimate weapon against the COVID-19 pandemic, vaccines will play a vital role in the economic development and social stability of the entire world. I would like to thank the National Medical Products Administration for their great support and for their approval of the clinical trial and we will continue our close collaboration with BioNTech. We are working together and moving...